Distinguished in Epilepsy with Myoclonic-Atonic Seizures

Michael I. Lock

Royal Botanic Gardens, 
Richmond, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Epilepsy with Myoclonic-Atonic Seizures
Royal Botanic Gardens, 
Richmond, ENG, GB 
OverviewLocationsClinical Research

Overview

Michael Lock practices in Richmond, United Kingdom. Mr. Lock is rated as a Distinguished expert by MediFind in the treatment of Epilepsy with Myoclonic-Atonic Seizures. His top areas of expertise are Myoclonic Epilepsy, Dravet Syndrome, Epilepsy with Myoclonic-Atonic Seizures, Lennox-Gastaut Syndrome (LGS), and Mastectomy.

His clinical research consists of co-authoring 140 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Epilepsy with Myoclonic-Atonic Seizures.

Gender
Male

Locations

Royal Botanic Gardens, Richmond, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III Randomized Trial of Standard Dose Stereotactic Body Radiation Therapy (SBRT) Versus Radiobiologically-Guided Dose Selected SBRT in Primary or Secondary Liver Carcinoma (SAVIOR).
A Phase III Randomized Trial of Standard Dose Stereotactic Body Radiation Therapy (SBRT) Versus Radiobiologically-Guided Dose Selected SBRT in Primary or Secondary Liver Carcinoma (SAVIOR).
Enrollment Status: Recruiting
Publish Date: March 11, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: October 10, 2025
Intervention Type: Radiation, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer
A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2025
The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: an Adaptive Phase II/III Randomized Trial.
The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer with Oligometastases: an Adaptive Phase II/III Randomized Trial.
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2024
Intervention Type: Drug, Radiation
Study Drugs: Leuprolide acetate, Goserelin acetate, Triptorelin, Enzalutamide
Study Phase: Phase 2/Phase 3
Evaluation of the Ductal Carcinoma In Situ Score for Decisions on Radiotherapy in Patients With Low/Intermediate Risk DCIS
Evaluation of the Ductal Carcinoma In Situ Score for Decisions on Radiotherapy in Patients With Low/Intermediate Risk DCIS
Enrollment Status: Completed
Publish Date: February 19, 2020
Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Women With Breast Cancer Receiving Adjuvant Radiation Therapy
Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Women With Breast Cancer Receiving Adjuvant Radiation Therapy
Enrollment Status: Completed
Publish Date: March 08, 2017
Intervention Type: Device, Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

140 Total Publications

The Dilemma of Choice: Options for Nonoperable Hepatocellular Carcinoma Management.
The Dilemma of Choice: Options for Nonoperable Hepatocellular Carcinoma Management.
Journal: International journal of radiation oncology, biology, physics
Published: April 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lock's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile